Hypertension is a complex disease process involving many pathophysiological changes. In this program Project, the individual research topics focus on the theme that metabolic factors contribute to abnormal blood pressure regulation in hypertension. The strategy of the group is to monitor many relevant variables during the development of hypertension with the goal of defining the complete sequence of events from the introduction of an intervention (experimentally imposed, genetic or clinical_ to the resultant elevation in blood pressure. Among these variables are alterations in neural and endocrine factors, cellular events and molecular and genetic characteristics. Five principal investigators from four departments (three clinical and one basic science) have joined to study these changes. Animal models will include mice, experimental hypertension and transgenically modified), dogs and rats. Additionally, obesity-related hypertension in humans will be evaluated. Among the specific variables measured will be the following: mRNA for specific proteins, enzyme activities, genetic associations, vascular reactivity, blood pressure, hormonal levels, endothelium-derived products and fatty acid levels. Research strategies will utilize the professional expertise and equipment described in two of the three core units (Core B, Animal and Core C, Chemistry). Biostatistics support and scientific management will be coordinated through the Administrative Core (Core A). From these integrated projects, a better understanding of the initiating factors of hypertension will emerge.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Program Projects (P01)
Project #
Application #
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Barouch, Winifred
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Internal Medicine/Medicine
Schools of Medicine
Ann Arbor
United States
Zip Code
Rocchini, Albert P; Yang, John Q; Smith, Marla J et al. (2010) Serial changes in norepinephrine kinetics associated with feeding dogs a high-fat diet. J Clin Hypertens (Greenwich) 12:117-24
Kamal, Mohamed A; Keep, Richard F; Smith, David E (2008) Role and relevance of PEPT2 in drug disposition, dynamics, and toxicity. Drug Metab Pharmacokinet 23:236-42
Duan, Sheng Zhong; Ivashchenko, Christine Y; Whitesall, Steven E et al. (2007) Direct monitoring pressure overload predicts cardiac hypertrophy in mice. Physiol Meas 28:1329-39
Hu, Yongjun; Shen, Hong; Keep, Richard F et al. (2007) Peptide transporter 2 (PEPT2) expression in brain protects against 5-aminolevulinic acid neurotoxicity. J Neurochem 103:2058-65
Ennis, Steven R; Keep, Richard F (2007) Effect of sustained-mild and transient-severe hyperglycemia on ischemia-induced blood-brain barrier opening. J Cereb Blood Flow Metab 27:1573-82
Shen, Hong; Ocheltree, Scott M; Hu, Yongjun et al. (2007) Impact of genetic knockout of PEPT2 on cefadroxil pharmacokinetics, renal tubular reabsorption, and brain penetration in mice. Drug Metab Dispos 35:1209-16
Xiang, Jianming; Chiang, Pei-Pei; Hu, Yongjun et al. (2006) Role of PEPT2 in glycylsarcosine transport in astrocyte and glioma cultures. Neurosci Lett 396:225-9
Ennis, S R; Keep, R F (2006) Effects of 2,4-dinitrophenol on ischemia-induced blood-brain barrier disruption. Acta Neurochir Suppl 96:295-8
Carello, Katari A; Whitesall, Steven E; Lloyd, Mary C et al. (2006) Asymmetrical dimethylarginine plasma clearance persists after acute total nephrectomy in rats. Am J Physiol Heart Circ Physiol 290:H209-16
Xiang, Jianming; Hu, Yongjun; Smith, David E et al. (2006) PEPT2-mediated transport of 5-aminolevulinic acid and carnosine in astrocytes. Brain Res 1122:18-23

Showing the most recent 10 out of 291 publications